SUVOREXANT

Search structure


Trade Names:	BELSOMRA
Synonyms:	Belsomra MK-4305 MK4305 Suvorexant
Status:	Approved (2014)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	N05CM19
UNII:	081L192FO9

Structure


InChI Key	JYTNQNCOQXFQPK-MRXNPFEDSA-N
Smile	Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1
InChI	InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H23ClN6O2
Molecular Weight	450.93
AlogP	4.11
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	3.0
Polar Surface Area	80.29
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	32.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Orexin receptor antagonist	FDA

	Primary Target
OX₁ receptor
OX₂ receptor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Orexin receptor	-	0-138	-	0-3	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Delirium	3	D003693	ClinicalTrials
Alzheimer Disease	2	D000544	ClinicalTrials
Restless Legs Syndrome	2	D012148	ClinicalTrials
Sleep Wake Disorders	2	D012893	ClinicalTrials
Alcoholism	2	D000437	ClinicalTrials
Smoking Cessation	2	D016540	ClinicalTrials
Opioid-Related Disorders	2	D009293	ClinicalTrials
Sleep Apnea Syndromes	1	D012891	ClinicalTrials
Tobacco Use Disorder	1	D014029	ClinicalTrials

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	7.0
Nervous system disorders Somnolence	7.0
Nervous system disorders Headache
Cardiac disorders Dizziness	3.0
Nervous system disorders Somnolence
Nervous system disorders Abnormal dreams	2.0
Respiratory, thoracic and mediastinal disorders Cough	2.0
Gastrointestinal disorders Diarrhoea	2.0
Cardiac disorders Dizziness
Gastrointestinal disorders Dry mouth	2.0
Infections and infestations Upper respiratory tract infection	2.0
Nervous system disorders Abnormal dreams
Respiratory, thoracic and mediastinal disorders Cough
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Dry mouth
Infections and infestations Upper respiratory tract infection

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Psychiatric disorders	26.5
General disorders and administration site conditions	24.43
Nervous system disorders	22.81
Injury, poisoning and procedural complications	6.17
Gastrointestinal disorders	3.42
Cardiac disorders	2.72
Musculoskeletal and connective tissue disorders	2.17
Vascular disorders	2.08
Respiratory, thoracic and mediastinal disorders	2.02

Cross References

Resources	Reference
CAS NUMBER	1030377-33-3
ChEBI	82698
ChEMBL	CHEMBL1083659
DrugBank	DB09034
DrugCentral	4881
EPA CompTox	DTXSID90145616
FDA SRS	081L192FO9
Guide to Pharmacology	2890
PDB	SUV
PubChem	24965990
SureChEMBL	SCHEMBL1586289
ZINC	ZINC000049036447

CONTENTS